Ampulla of Vater Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: AMP013 MIFTS: 39	Ampulla of Vater Cancer Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Ampulla of Vater Cancer

MalaCards integrated aliases for Ampulla of Vater Cancer:

Name: Ampulla of Vater Cancer ¹² ¹² ¹⁵

Ampulla of Vater Carcinoma ¹² ¹⁵ ¹⁷

Ampullary Carcinoma ¹² ⁵⁸

Malignant Tumour of Ampulla of Vater ¹²

Carcinoma of the Ampulla of Vater ⁵⁸

Carcinoma of Ampulla of Vater ¹²

Ampulloma ⁵⁸

Characteristics:

Orphanet epidemiological data:

⁵⁸

carcinoma of the ampulla of vater
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Gastrointestinal diseases

See all MalaCards categories (disease lists)

ICD10: ³² ³³

Neoplasms

Malignant neoplasms of digestive organs

Malignant neoplasm of other and unspecified parts of biliary tract

Malignant neoplasm: Ampulla of Vater

Orphanet: ⁵⁸

Rare gastroenterological diseases

External Ids:

Disease Ontology ¹² DOID:10020 DOID:4932

ICD9CM ³⁴ 156.2

NCIt ⁴⁹ C3536 C3908

SNOMED-CT ⁶⁷ 93668007

ICD10 ³² C24.1

ICD10 via Orphanet ³³ C24.1

UMLS via Orphanet ⁷² C0262401

Orphanet ⁵⁸ ORPHA300557

EFO ¹⁷ EFO_1000079

UMLS ⁷¹ C0153454 C0262401

Sources

Summaries for Ampulla of Vater Cancer

MalaCards based summary : Ampulla of Vater Cancer, also known as ampulla of vater carcinoma, is related to ampulla of vater neoplasm and microinvasive gastric cancer. An important gene associated with Ampulla of Vater Cancer is MIR196A1 (MicroRNA 196a-1), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and MicroRNAs in cancer. The drugs Oxaliplatin and Capecitabine have been mentioned in the context of this disorder. Affiliated tissues include colon, lung and thyroid, and related phenotype is digestive/alimentary.

Sources

Related Diseases for Ampulla of Vater Cancer

Diseases related to Ampulla of Vater Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 359)

#	Related Disease	Score	Top Affiliating Genes
1	ampulla of vater neoplasm	30.6	KRAS HRAS
2	microinvasive gastric cancer	30.6	MUC6 MUC5AC MIR196A1 CDX2
3	papillary adenocarcinoma	30.6	MUC1 KRT7 KRAS
4	small cell carcinoma	30.5	MUC1 KRT7 KRT20 KRAS CDX2
5	spindle cell carcinoma	30.5	MUC1 KRT7 HRAS
6	cholecystitis	30.4	MUC6 MUC5AC MUC1
7	neuroendocrine carcinoma	30.4	MUC1 KRT7 KRT20
8	adenosquamous carcinoma	30.3	SMAD4 MUC1 KRT7 KRAS
9	in situ carcinoma	30.3	MUC1 KRT17 HRAS
10	familial adenomatous polyposis	30.2	SMAD4 PTGS2 KRAS HRAS
11	ampulla of vater adenocarcinoma	29.9	MUC5AC MUC1 MIR377 MIR30B MIR222 MIR196A1
12	papilloma	29.9	PTGS2 KRT7 KRT20 KRAS
13	gallbladder cancer	29.8	SMAD4 PTGS2 MUC1 MIR145 KRT7 KRAS
14	large intestine cancer	29.7	MIR222 MIR196A1 MIR181A1 MIR145 KRAS HRAS
15	large cell carcinoma	29.7	MUC1 KRT7 KRT20 KRAS HRAS
16	cholangitis, primary sclerosing	29.6	MIR222 MIR145 KRT7
17	tubular adenocarcinoma	29.5	MUC5AC MUC1 KRT7 KRT20 CDX2
18	lynch syndrome	29.5	SMAD4 KRAS HRAS AGR2
19	cystadenoma	29.4	MUC6 MUC5AC MUC1 KRT7 KRT20
20	bladder cancer	29.3	PTGS2 MUC1 MIR222 MIR145 KRT20 KRAS
21	pancreatic ductal adenocarcinoma	29.2	SMAD4 MUC1 MIR222 MIR196A1 MIR145 KRAS
22	intrahepatic cholangiocarcinoma	29.1	SMAD4 MUC5AC MUC1 KRT7 KRT20 KRAS
23	adenoma	29.0	SMAD4 PTGS2 MUC6 MUC5AC MUC1 KRT7
24	pancreatic ductal carcinoma	28.9	SMAD4 MUC6 MUC5AC MUC1 KRT7 KRT20
25	cholangiocarcinoma	28.9	SMAD4 PTGS2 MUC5AC MUC1 KRT7 KRT20
26	adenocarcinoma	28.8	SMAD4 PTGS2 MUC1 KRT7 KRT20 KRAS
27	ovarian serous cystadenocarcinoma	28.7	SMAD4 MUC6 MUC5AC MUC1 MIR196A1 KRAS
28	bile duct cancer	28.7	SMAD4 MUC6 MUC5AC MUC1 KRT7 KRT20
29	signet ring cell adenocarcinoma	28.4	MUC6 MUC5AC MUC1 KRT7 KRT20 KRAS
30	pancreatic adenocarcinoma	28.4	SMAD4 PTGS2 MUC6 MUC5AC MUC1 MIR196A1
31	gastric adenocarcinoma	28.2	SMAD4 PTGS2 MUC1 KRT7 KRT20 KRT17
32	pancreatic cancer	27.4	SMAD4 PTGS2 MUC6 MUC5AC MUC1 MIR222
33	gastric cancer	27.4	SMAD4 PTGS2 MUC6 MUC5AC MUC1 MIR222
34	ovarian cancer	27.4	SMAD4 PTGS2 MUC5AC MUC1 MIR377 MIR222
35	colorectal cancer	26.9	SMAD4 PTGS2 MUC6 MUC5AC MUC1 MIR196A1
36	ampulla of vater squamous cell carcinoma	11.5
37	ampulla of vater adenosquamous carcinoma	11.5
38	large cell neuroendocrine carcinoma	10.6
39	bladder signet ring cell adenocarcinoma	10.5	KRT7 CDX2
40	ovary neuroendocrine neoplasm	10.5	KRT7 CDX2
41	anal canal paget's disease	10.5	KRT7 CDX2
42	anal paget's disease	10.5	KRT7 CDX2
43	ureter adenocarcinoma	10.5	KRT7 CDX2
44	adenosquamous colon carcinoma	10.5	KRT7 CDX2
45	anus adenocarcinoma	10.5	KRT7 CDX2
46	mucinous adenofibroma	10.5	KRT7 CDX2
47	scrotum paget's disease	10.5	MUC1 KRT7
48	rectum neuroendocrine neoplasm	10.5	KRT7 CDX2
49	ovarian seromucinous carcinoma	10.5	KRT7 CDX2
50	gallbladder signet ring cell adenocarcinoma	10.5	MUC1 KRT7

Graphical network of the top 20 diseases related to Ampulla of Vater Cancer:

Sources

Symptoms & Phenotypes for Ampulla of Vater Cancer

MGI Mouse Phenotypes related to Ampulla of Vater Cancer:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.23	AGR2 CDX2 HRAS KRAS KRT17 MUC5AC

Sources

Drugs & Therapeutics for Ampulla of Vater Cancer

Drugs for Ampulla of Vater Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

5310940 9887054 6857599 43805

Synonyms:

CHEMBL1201055

CID9887054

D01790

DACPLAT

Diaminocyclohexane Oxalatoplatinum

Eloxatin

Eloxatin (TN)

Elplat

Foloxatine

L-OHP

Oxalatoplatin

Oxalatoplatinum

oxaliplatin

Oxaliplatin

Oxaliplatin (JAN/USAN/INN)

Oxaliplatin [Usan:Inn:Ban]

oxaliplatine

oxaliplatino

Oxaliplatino [Spanish]

oxaliplatinum

Oxaliplatinum [Latin]

Oxaloplatine [French]

Oxaloplatino [Spanish]

Transplatin

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Synonyms:

(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester

(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester

(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester

(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester

154361-50-9

158798-73-3

5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine

5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine

AC1L1U83

AC1Q4KU8

Ambap154361-50-9

C110904

C12650

C15H22FN3O6

CAPE

Capecitabin

capecitabina

Capecitabina

capecitabine

Capecitabine

CAPECITABINE

Capécitabine

Capecitabine (JAN/USAN/INN)

Capecitabine [USAN]

capecitabinum

Capecitabinum

Capecitibine

Capiibine

Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester

Caxeta

CHEBI:31348

CHEMBL1773

CID60953

D01223

DB01101

FT-0082472

HSDB 7656

LS-59070

MolPort-005-938-254

N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine

Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid

Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid

Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate

Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid

Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid

Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid

pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate

Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid

pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate

R340

R-340

RG-340

Ro 09-1978

Ro 09-1978/000

Ro-09-1978

Ro-09-1978/000

S1156_Selleck

UNII-6804DJ8Z9U

Xabine

Xeloda

Xeloda (TN)

Xeloda, Captabin, Capecitabine

ZINC03806413

Gemcitabine

Approved

Phase 2

95058-81-4

60750

Synonyms:

103882-84-4

122111-03-9

2',2'-DFDC

2',2'-DiF-dC

2',2'-difluoro-2'-Deoxycytidine

2',2'-Difluoro-2'-deoxycytidine

2',2'-Difluorodeoxycytidine

2'-Deoxy-.beta.-D-2',2'-difluorocytidine

2'-Deoxy-2',2'-difluorocytidine

2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate

2'-Deoxy-2'-difluorocytidine

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-amino-1-((2R,4R,5R)-3,3-difluoro-4-Hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one

4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one

4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one

95058-81-4

AB1004842

AC1L1TUQ

C07650

CCRIS 8984

CHEBI:175901

CHEMBL888

CID60750

Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine

D02368

DB00441

DDFC

DFdC

DFDC

DFdCyd

Folfugem

Gamcitabine

Gemcel

Gemcin

Gemcitabin

Gemcitabina

Gemcitabina [INN-Spanish]

gemcitabine

Gemcitabine

Gemcitabine (USAN/INN)

Gemcitabine HCl

Gemcitabine hydrochloride

Gemcitabine stereoisomer

Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer

Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer

Gemcitabine, (D-threo-pentafuranosyl)-isomer

Gemcitabinum

Gemcitabinum [INN-Latin]

GemLip

Gemtro

Gemzar

Gemzar (hydrochloride)

GEO

HMS2089P10

HSDB 7567

Inno-D07001

LS-59139

LY 188011

LY188011

LY-188011

NCGC00168784-01

NChemBio.2007.10-comp25

nchembio.573-comp7

nchembio.90-comp2

NSC 613327

NSC613327

TL8005979

UNII-B76N6SBZ8R

Zefei

ZINC18279854

Rucaparib

Approved, Investigational

Phase 2

283173-50-2

9931954

s 1 (combination)

Phase 2

Antimetabolites

Phase 2

Immunologic Factors

Phase 2

Anti-Infective Agents

Phase 2

Antiviral Agents

Phase 2

Immunosuppressive Agents

Phase 2

Poly(ADP-ribose) Polymerase Inhibitors

Phase 2

Cola

Phase 2

Irinotecan

Approved, Investigational

Phase 1

97682-44-5, 100286-90-6

60838

Synonyms:

(+)-Irinotecan

(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE

(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate

1u65

7-Ethyl-10-hydroxycamptothecin

97682-44-5

AC1L1U0Z

AC1Q6PGI

AC-7469

Bio-0054

Biotecan

Biotecan (TN)

BRD-K08547377-003-02-4

BSPBio_002346

C16641

C33H38N4O6

Campothecin-11

Campto

Camptosar

Camptosar, Campto, CPT-11, Irinotecan

Camptothecin-11

CHEBI:105985

CHEMBL481

CID60838

CP0

CPT 11

CPT-11

D08086

DB00762

FT-0083650

HSDB 7607

Irinophore C

irinotecan

Irinotecan

Irinotecan (INN)

Irinotecan [INN:BAN]

Irinotecan Hcl

Irinotecan hydrochloride

Irinotecan Hydrochloride

Irinotecan hydrochloride trihydrate

Irinotecan Hydrochloride Trihydrate

IRINOTECAN HYDROCHLORIDE Trihydrate

Irinotecan lactone

Irinotecan mylan

IRINOTECAN, CPT-11

Irinotecanum

Irinotecanum [INN-Latin]

Irrinotecan

LS-44589

NCI60_005051

NK012 Compound

NSC728073

S1198_Selleck

sn 38

sn-38

sn38 CPD

TL8006026

UNII-7673326042

Pancrelipase

Approved, Investigational

Phase 1

53608-75-6

topoisomerase I inhibitors

Phase 1

Topoisomerase Inhibitors

Phase 1

pancreatin

Phase 1

Iodine

Approved, Investigational

7553-56-2

807

Synonyms:

diiodine

Iode

Iodine-molecule

Iodio

iodo

Iodum

Jod

Jood

molecular iodine

Molecular iodine

Tincture iodine

cadexomer iodine

Interventional clinical trials:

(show all 20)

#	Name	Status	NCT ID	Phase	Drugs
1	An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma	Unknown status	NCT01180153	Phase 2	S-1 oxaliplatin
2	A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater	Completed	NCT00354887	Phase 2	Capecitabine;Oxaliplatin
3	A Randomized, Multicentre, Phase II, Parallel-Group Trial of Vandetanib Monotherapy or Vandetanib in Combination With Gemcitabine Versus Gemcitabine Plus Vandetanib Matching Placebo in Subjects With Advanced Biliary Tract Cancer (Gallbladder Cancer, Cancer of the Extrahepatic Bile Duct, Intrahepatic Cholangiocarcinoma and Ampullary Carcinoma)	Completed	NCT00753675	Phase 2	ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
4	Phase 2 Study of Randomized Controlled Trial of Pancreatic Enzyme Supplementation in Patients With Unresectable Pancreatic Cancer	Completed	NCT01587534	Phase 2	Norzyme
5	A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes	Not yet recruiting	NCT04171700	Phase 2	Rucaparib
6	A Phase II Study to Evaluate the Response and Tolerability of Verzenio (Abemaciclib) in Patients With Advanced Biliary Tract Carcinoma Who Have Failed Prior Chemotherapy	Not yet recruiting	NCT04003896	Phase 2	Abemaciclib
7	Phase I Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers	Completed	NCT00183846	Phase 1	irinotecan
8	Intraluminal Implantation of Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer	Unknown status	NCT02238613
9	Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors	Unknown status	NCT02665494
10	Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis: A Prospective Clinical, Immunopathologic and Molecular Analysis	Unknown status	NCT02656134
11	Comparison Between Endoscopic Stenting and Cholecystojejunostomy for PreoperativeDrainage Before Pancreaticoduodenectomy	Unknown status	NCT01913275
12	The Pre-operative Pathway in Pancreatic Head Malignancy-assessment of the Diagnostic Accuracy of Staging CT Scan	Completed	NCT02296736
13	Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation. A Prospective Randomized Study	Completed	NCT02477228
14	Endoscopic Papillectomy for Ampullary Adenomas: an Italian Single Centre Experience	Completed	NCT03494543
15	to Evaluate the Long-term Results of Endoscopic Papillectomy (EP)	Completed	NCT01764503
16	Endoscopic Ultrasound Evaluation of the Common Bile Duct in Patients With Obstructive Jaundice Due to Bilio-Pancreatic Malignancies: A Multicenter Prospective Study	Recruiting	NCT03494023
17	Study of Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma	Recruiting	NCT03800212		treatment for ampullary adenocarcinoma
18	Endoscopic Radiofrequency Ablation for Malignant Biliary Strictures Due to Unresectable Cholangiocarcinoma or Ampullary Carcinoma: a Randomised, Controlled, Multicentre Clinical Trial	Recruiting	NCT01844245
19	Periampullary Lesions Via ERCP in Assuit University Hospital	Recruiting	NCT03185390
20	COMPLICATIONS OF ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY- AN INDIAN PERSPECTIVE	Active, not recruiting	NCT04062617

Search NIH Clinical Center for Ampulla of Vater Cancer

Sources

Genetic Tests for Ampulla of Vater Cancer

Sources

Anatomical Context for Ampulla of Vater Cancer

MalaCards organs/tissues related to Ampulla of Vater Cancer:

⁴⁰

Colon, Lung, Thyroid, Breast, Pancreas, Ovary, Appendix

Sources

Publications for Ampulla of Vater Cancer

Articles related to Ampulla of Vater Cancer:

(show top 50) (show all 103)

#	Title	Authors	PMID	Year
1	Influence of bile contamination for patients who undergo pancreaticoduodenectomy after biliary drainage. ⁶¹	Okano K...Suzuki Y	31885425	2019
2	Smoking, Alcohol, and Biliary Tract Cancer Risk: A Pooling Project of 26 Prospective Studies. ⁶¹	McGee EE...Koshiol J	31127946	2019
3	ASO Author Reflections: The Accurate Prognostic Evaluation and Optimal Treatment Strategy for Ampulla of Vater Carcinoma. ⁶¹	Imamura T...Uesaka K	31115854	2019
4	[Prediction model for survival in patients with biliary tract cancer: a development and validation study]. ⁶¹	Han L...Zhang B	31838822	2019
5	Laparoscopic pancreaticoduodenectomy for periampullary tumors: lessons learned from 500 consecutive patients in a single center. ⁶¹	Song KB...Park G	31214805	2019
6	Effects of aspirin and non-steroidal anti-inflammatory drugs on the risk of cholangiocarcinoma: a meta-analysis. ⁶¹	Lapumnuaypol K...Cheungpasitporn W	30753687	2019
7	Role of systemic inflammation in predicting the prognosis of ampulla of Vater carcinoma. ⁶¹	Seo HK...Kim SC	31196491	2019
8	The Prognostic Relevance of the New 8th Edition of the Union for International Cancer Control Classification of TNM Staging for Ampulla of Vater Carcinoma. ⁶¹	Imamura T...Uesaka K	30790111	2019
9	Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013. ⁶¹	Van Dyke AL...Koshiol J	30645774	2019
10	Incidence and Mortality Rates of Second Pancreatic Cancer Among Survivors of Digestive Cancers: A Nationwide Population-Based Study. ⁶¹	Ahn HS...Park SM	30768577	2019
11	Factors Associated with Malignant Biliary Strictures in Patients with Atypical or Suspicious Cells on Brush Cytology. ⁶¹	Park JY...Jeon TJ	30625267	2019
12	Associations between autoimmune conditions and hepatobiliary cancer risk among elderly US adults. ⁶¹	McGee EE...Koshiol J	30155920	2019
13	Perineural Invasion is a Strong Prognostic Moderator in Ampulla of Vater Carcinoma: A Meta-analysis. ⁶¹	Luchini C...Scarpa A	30451797	2019
14	Ampulla of Vater carcinoma: Molecular landscape and clinical implications. ⁶¹	Pea A...Luchini C	30487949	2018
15	Sarcomatoid Adenocarcinoma of the Ampulla of Vater. ⁶¹	Jung JH...Mun YS	29887717	2018
16	Validation of the eighth edition of the American Joint Committee on Cancer staging system for ampulla of Vater cancer. ⁶¹	Kim SJ...Hong SM	29452703	2018
17	The prognostic impact of differentiation at the invasive front of biliary tract cancer. ⁶¹	Okubo S...Konishi M	29572828	2018
18	Ampullary carcinoma-A genetic perspective. ⁶¹	Jayaramayya K...Santhy KS	29807574	2018
19	Impact of preoperative endoscopic cholangiography and biliary drainage in Ampulla of Vater cancer. ⁶¹	Ahn KS...Lee JW	29549909	2018
20	Survival rates are higher in married patients with biliary tract cancer: a population-based study. ⁶¹	Song W...Chen L	29507708	2018
21	Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations. ⁶¹	Mafficini A...Scarpa A	27611608	2018
22	PD-L1 overexpression in ampulla of Vater carcinoma and its pre-invasive lesions. ⁶¹	Saraggi D...Rugge M	28502094	2017
23	Proposed new staging system for ampulla of Vater cancer with greater discriminatory ability: multinational study from eastern and western centers. ⁶¹	He J...Jang JY	28660632	2017
24	Impact of delayed gastric emptying after pancreaticoduodenectomy on survival. ⁶¹	Futagawa Y...Yanaga K	28547910	2017
25	Genetic alterations in Japanese extrahepatic biliary tract cancer. ⁶¹	Noguchi R...Furukawa Y	28693246	2017
26	Bilateral lung metastasectomy in carcinoma of the ampulla of Vater. ⁶¹	Pih GY...Chang HM	28168842	2017
27	Metastasectomy for recurrent or metastatic biliary tract cancers: A single center experience. ⁶¹	Park I...Shin DB	29199665	2017
28	Diet and biliary tract cancer risk in Shanghai, China. ⁶¹	Nelson SM...Koshiol J	28288186	2017
29	Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy. ⁶¹	Ha H...Oh DY	27780932	2016
30	KRAS mutation as a prognostic factor in ampullary adenocarcinoma: a meta-analysis and review. ⁶¹	Kim BJ...Lee J	27517148	2016
31	Genomic Alterations in Biliary Tract Cancer Using Targeted Sequencing. ⁶¹	Yoo KH...Park JO	27267833	2016
32	The clinical characteristics and manifestations of cytomegalovirus esophagitis. ⁶¹	Wang HW...Chen KH	25715747	2016
33	Transduodenal Ampullectomy for the Treatment of Early-Stage Ampulla of Vater Cancer. ⁶¹	Lee H...Choi SH	26546182	2016
34	Total Laparoscopic Pancreaticoduodenectomy Using a New Technique of Pancreaticojejunostomy with Two Transpancreatic Sutures with Buttresses. ⁶¹	Kim EY...Hong TH	26717322	2016
35	Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas. ⁶¹	Pinto P...Teixeira MR	27532258	2016
36	Survival Outcomes According to Adjuvant Treatment and Prognostic Factors Including Host Immune Markers in Patients with Curatively Resected Ampulla of Vater Cancer. ⁶¹	Ha HR...Bang YJ	26974670	2016
37	Prognostic impact of immunohistochemical expression of CK7 and CK20 in curatively resected ampulla of Vater cancer. ⁶¹	Yun SP...Seo HI	26603157	2015
38	Metabolic Characteristics of Advanced Biliary Tract Cancer Using 18F-Fluorodeoxyglucose Positron Emission Tomography and Their Clinical Implications. ⁶¹	Cho KM...Bang YJ	26099746	2015
39	Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. ⁶¹	Kwon J...Ha SW	25775067	2015
40	Metachronous Ampulla of Vater Carcinoma after Curative-Intent Surgery for Klatskin Tumor. ⁶¹	Chirita D...Dumitrascu T	26305204	2015
41	Ampulla of Vater carcinoma in real-world clinical practice: a case series. ⁶¹	Giuliani J...Bonetti A	25908045	2015
42	Salvage radiation therapy for isolated local recurrence of extrahepatic cholangiocarcinoma after radical surgery: a retrospective study. ⁶¹	Kim SW...Park YS	25319582	2015
43	Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC). ⁶¹	Ji JH...Kang JH	25628352	2015
44	Variants in motilin, somatostatin and their receptor genes and risk of biliary tract cancers and stones in Shanghai, China. ⁶¹	Xu HL...Gao YT	24999450	2014
45	Knockdown of anterior gradient 2 expression extenuates tumor-associated phenotypes of SNU-478 ampulla of Vater cancer cells. ⁶¹	Kim SJ...Kang D	25367337	2014
46	Role of SpyGlass peroral cholangioscopy in the evaluation of indeterminate biliary lesions. ⁶¹	Woo YS...Lee KT	24788322	2014
47	Reporting tumor molecular heterogeneity in histopathological diagnosis. ⁶¹	Mafficini A...Scarpa A	25127237	2014
48	Collision tumor of the ampulla of Vater - Coexistence of neuroendocrine carcinoma and adenocarcinoma: report of a case. ⁶¹	Kim HJ...Hur YH	26155238	2013
49	A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity. ⁶¹	Kobrinsky B...Hochster H	24048674	2013
50	Biliary tract cancer incidence in the United States-Demographic and temporal variations by anatomic site. ⁶¹	Castro FA...Devesa SS	23504585	2013

Sources

Genes for Ampulla of Vater Cancer

Genes related to Ampulla of Vater Cancer (0 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	MIR196A1	MicroRNA 196a-1	RNA Gene	18.24	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ ¹⁵
2	MIR377	MicroRNA 377	RNA Gene	17.67	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ ¹⁵
3	MIR187	MicroRNA 187	RNA Gene	16.02	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ ¹⁵
4	MIR145	MicroRNA 145	RNA Gene	15.38	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ ¹⁵
5	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	14.81	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
6	AGR2	Anterior Gradient 2, Protein Disulphide Isomerase Family Member	Protein Coding	14.68	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : Publications (show sections)
7	CDX2	Caudal Type Homeobox 2	Protein Coding	14.37	DISEASES inferred ¹⁵ ¹⁵
8	MIR30B	MicroRNA 30b	RNA Gene	14.3	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ ¹⁵
9	KRT7	Keratin 7	Protein Coding	14.16	DISEASES inferred ¹⁵ ¹⁵
10	MIR181A1	MicroRNA 181a-1	RNA Gene	14.1	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ ¹⁵
11	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	13.66	DISEASES inferred ¹⁵ ¹⁵
12	MIR222	MicroRNA 222	RNA Gene	13.65	DISEASES inferred ¹⁵ ¹⁵ ¹⁵ ¹⁵
13	MUC5AC	Mucin 5AC, Oligomeric Mucus/Gel-Forming	Protein Coding	13.38	DISEASES inferred ¹⁵ ¹⁵
14	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	13.25	DISEASES inferred ¹⁵ ¹⁵
15	MUC6	Mucin 6, Oligomeric Mucus/Gel-Forming	Protein Coding	13.01	DISEASES inferred ¹⁵ ¹⁵
16	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	12.92	DISEASES inferred ¹⁵ ¹⁵
17	SMAD4	SMAD Family Member 4	Protein Coding	12.73	DISEASES inferred ¹⁵ ¹⁵
18	KRT20	Keratin 20	Protein Coding	12.43	DISEASES inferred ¹⁵ ¹⁵
19	KRT17	Keratin 17	Protein Coding	12.39	DISEASES inferred ¹⁵ ¹⁵
20	AACS	Acetoacetyl-CoA Synthetase	Protein Coding	12.34	DISEASES inferred ¹⁵ ¹⁵
21	ELF3	E74 Like ETS Transcription Factor 3	Protein Coding	12.24	DISEASES inferred ¹⁵ ¹⁵
22	MIR614	MicroRNA 614	RNA Gene	11.97	DISEASES inferred ¹⁵ ¹⁵

Sources

Variations for Ampulla of Vater Cancer

Sources

Expression for Ampulla of Vater Cancer

Search GEO for disease gene expression data for Ampulla of Vater Cancer.

Sources

Pathways for Ampulla of Vater Cancer

Pathways related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	CLEC7A (Dectin-1) signaling ⁶⁵ Show member pathways Alternative NF-kappaB pathway ¹ CLEC7A/inflammasome pathway ⁶⁵ C-type lectin receptors (CLRs) ⁶⁵	11.77	MUC6 MUC5AC MUC1 KRAS HRAS
2	MicroRNAs in cancer ³⁶	11.66	PTGS2 MIR30B MIR222 MIR181A1 MIR145 KRAS
3	miRNAs involved in DNA damage response ¹	11.2	MIR222 MIR181A1 MIR145
4	Aryl Hydrocarbon Receptor ¹	11.11	PTGS2 KRAS HRAS
5	Extracellular vesicle-mediated signaling in recipient cells ¹	10.81	SMAD4 KRAS HRAS
6	p38MAPK events ⁶⁵	10.48	KRAS HRAS

Sources

GO Terms for Ampulla of Vater Cancer

Biological processes related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	O-glycan processing	GO:0016266	9.43	MUC6 MUC5AC MUC1
2	gene silencing by miRNA	GO:0035195	9.43	MIR30B MIR222 MIR196A1 MIR187 MIR181A1 MIR145
3	response to isolation stress	GO:0035900	9.16	KRAS HRAS
4	stimulatory C-type lectin receptor signaling pathway	GO:0002223	9.02	MUC6 MUC5AC MUC1 KRAS HRAS

Molecular functions related to Ampulla of Vater Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	mRNA binding involved in posttranscriptional gene silencing	GO:1903231	9.1	MIR30B MIR222 MIR196A1 MIR187 MIR181A1 MIR145

Sources

Sources for Ampulla of Vater Cancer

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia